Zydus Lifesciences Ltd - 532321 - MPS Compliance
MPS Compliance23-03-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives tentative approval from USFDA for Letermovir Tablets, 240 mg and 480 mg.23-03-2024
Zydus Lifesciences Ltd - 532321 - Disclosure Under Insider Trading Regulations
Form C under Regulation 7(2) SEBI (Prohibition of Insider Trading) Regulations, 201522-03-2024
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate22-03-2024
Zydus Lifesciences Ltd - 532321 - Extinguishment Of Equity Shares - Clarification
Extinguishment of equity shares - clarification19-03-2024
Cadila Pharmaceuticals launches novel iron injection
The injection accelerates improvement of haemoglobin levels and efficiently replenishes depletedironstores19-03-2024
Zydus Lifesciences Ltd - 532321 - Extinguishment Of Equity Shares (Revised)
Extinguishment of Equity Shares (revised)18-03-2024
Zydus Lifesciences Ltd - 532321 - Extinguishment Of Equity Shares
Extinguishment of Equity Shares18-03-2024
Zydus Lifesciences Ltd - 532321 - Disclosure Under Insider Trading Regulations
Form C under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.18-03-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from USFDA and 180 days CGT exclusivity for Finasteride and Tadalafil Cap Capsules.16-03-2024